A Phase 1/2 interventional study of Pegcetacoplan in Neovascular Age-related Macular Degeneration, sponsored by Apellis Pharmaceuticals, Inc.. Terminated at 4 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2020-09-16.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 405th largest by enrollment of the 491 interventional ones that give a count, is one of 30 that started in 2018, is one of 61 in phase 1/2, and was the 383rd registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 30 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 5 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of neovascular AMD with the following criteria met:
Female subjects must be:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pegcetacoplan
Study Drug
Also known as: APL-2
Number of Subjects Experiencing Ocular and Systemic Treatment-Emergent Adverse Events (TEAEs) Including by Maximum Severity
TEAEs were defined as those adverse events (AEs) that developed or worsened after the first dose of study drug, up to 30 days after the last dose. The severity of the TEAEs was classified as mild (asymptomatic/mild symptoms); moderate (minimal, local/non-invasive intervention indicated); severe (medically significant but not life-threatening); life-threatening or leading to death. The number of subjects experiencing 1 TEAE in each category is presented. A maximum of 7 injections of pegcetacoplan (per subject) and a maximum of 13 injections of anti-VEGF (per subject) were received during the study.
Time frame: Day 1 up to end of study (up to 1 year).
Mean Change From Baseline in SD-OCT Central Subfield Thickness (CST) up to 12 Months
The CST was measured using SD-OCT throughout the study and the mean change from baseline at each timepoint is presented for the study eye.
Time frame: Day 1 up to Day 360 (12 months).
Number of Subjects With Clinically Significant Change From Baseline in Physical Examination Findings, Vital Signs and Laboratory Parameters
Physical examinations, vital signs and laboratory parameters were monitored throughout the study and any subjects showing a clinically significant change from baseline over the study period are presented.
Time frame: Baseline (Screening or Day 1) up to end of study (up to 1 year).
Male and female subjects aged at least 60 years with a clinical diagnosis of neovascular age-related macular degeneration in the study eye were recruited to this Phase 1b/2, open-label study at 3 study centers in the United States conducted from 14 February 2018 until the last subject last visit on 05 April 2019.
| Milestone | 15 mg Pegcetacoplan |
|---|---|
| Started | 17 |
| Completed | 0 |
| Not completed | 17 |
| Withdrew: Study/site terminated by sponsor | 14 |
| Withdrew: Withdrawal by subject | 3 |
TEAEs were defined as those adverse events (AEs) that developed or worsened after the first dose of study drug, up to 30 days after the last dose. The severity of the TEAEs was classified as mild (asymptomatic/mild symptoms); moderate (minimal, local/non-invasive intervention indicated); severe (medically significant but not life-threatening); life-threatening or leading to death. The number of subjects experiencing 1 TEAE in each category is presented. A maximum of 7 injections of pegcetacoplan (per subject) and a maximum of 13 injections of anti-VEGF (per subject) were received during the study.
| Participants | 15 mg Pegcetacoplan |
|---|---|
| Any TEAEs | 15 |
| Ocular study eye TEAE | 14 |
| Nonocular TEAE | 7 |
| TEAE at least possibly related to study drug | 5 |
| TEAE at least possibly related to injection | 8 |
| Serious TEAEs | 4 |
| TEAEs leading to study drug discontinuation | 1 |
| TEAEs leading to death | 0 |
| Maximum severity: mild | 6 |
| Maximum severity: moderate | 6 |
| Maximum severity: severe | 3 |
| Maximum severity: life-threatening | 0 |
The CST was measured using SD-OCT throughout the study and the mean change from baseline at each timepoint is presented for the study eye.
| micrometers | 15 mg Pegcetacoplan |
|---|---|
| Day 30 | 12.9 ± 39.06 |
| Day 60 | 16.1 ± 66.99 |
| Day 90 | 15.1 ± 57.44 |
| Day 120 | 31.6 ± 68.33 |
| Day 150 | 34.8 ± 90.50 |
| Day 180 | 48.3 ± 92.21 |
| Day 210 | 18.5 ± 66.06 |
| Day 240 | 34.1 ± 66.35 |
| Day 270 | 49.2 ± 58.76 |
| Day 300 | 22.2 ± 73.29 |
| Day 330 | -0.7 ± 57.17 |
| Day 360 | -10.5 ± 48.67 |
Physical examinations, vital signs and laboratory parameters were monitored throughout the study and any subjects showing a clinically significant change from baseline over the study period are presented.
| Participants | 15 mg Pegcetacoplan |
|---|---|
| Physical examination findings | 2 |
| Vital signs | 0 |
| Laboratory parameters | 0 |
Collected over Day 1 up to end of study (up to 1 year).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 15 mg Pegcetacoplan: Ocular Study Eye | 0/17 (0%) | 3/17 (17.6%) | 13/17 (76.5%) |
| 15 mg Pegcetacoplan: Ocular Fellow Eye | 0/17 (0%) | 0/17 (0%) | 3/17 (17.6%) |
| 15 mg Pecgectacoplan: Non-ocular | 0/17 (0%) | 1/17 (5.9%) | 6/17 (35.3%) |
| Event | 15 mg Pegcetacoplan: Ocular Study Eye | 15 mg Pegcetacoplan: Ocular Fellow Eye | 15 mg Pecgectacoplan: Non-ocular |
|---|---|---|---|
| UveitisEye disorders | 2/17 | 0/17 | 0/17 |
| Non-infectious endophthalmitisEye disorders | 1/17 | 0/17 | 0/17 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/17 | 0/17 | 1/17 |
| Event | 15 mg Pegcetacoplan: Ocular Study Eye | 15 mg Pegcetacoplan: Ocular Fellow Eye | 15 mg Pecgectacoplan: Non-ocular |
|---|---|---|---|
| Intraocular pressure increasedInvestigations | 5/17 | 0/17 | 0/17 |
| Conjunctival haemorrhageEye disorders | 3/17 | 0/17 | 0/17 |
| UveitisEye disorders | 2/17 | 0/17 | 0/17 |
| Vision blurredEye disorders | 2/17 | 0/17 | 0/17 |
| Ocular hypertensionEye disorders | 2/17 | 0/17 | 0/17 |
| PhotopsiaEye disorders | 2/17 | 0/17 | 0/17 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/17 | 0/17 | 2/17 |
| Eye painEye disorders | 1/17 | 0/17 | 0/17 |
| Posterior capsule opacificationEye disorders | 1/17 | 0/17 | 0/17 |
| Visual acuity reducedEye disorders | 1/17 | 0/17 | 0/17 |
The safety set included all subjects who received at least 1 dose of pegcetacoplan.
| Age, Continuous(years) | 15 mg Pegcetacoplan |
|---|---|
| Mean | 77.2 ± 8.76 |
| Sex: Female, Male(Participants) | 15 mg Pegcetacoplan |
|---|---|
| Female | 7 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | 15 mg Pegcetacoplan |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 17 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | 15 mg Pegcetacoplan |
|---|---|
| White | 16 |
| Native Hawaiian or Other Pacific Islander | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Apr 2019, 13 months.
Results were first posted in Sep 2020, 1 year 5 months after primary completion. A results delay was requested in Jul 2020.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Apellis Pharmaceuticals, Inc. →